* If you want to update the article please login/register
Abstract Background The nonsquamous non-u2013small cell lung cancer treatment of nonsquamous non-u2013small cell lung cancer has undergone a paradigm shift toward platinum combination therapy, as well as immune checkpoint inhibitors. However, phase III trials of cytotoxic chemotherapy and ICIs in combination with cytotoxic chemotherapy and ICIs have only included patients with stable organ function, not those with renal impairment. Discussion If the report shows the effectiveness and safety of carboplatin/nab-paclitaxel/atezolizumab, this combination therapy may be a treatment option for non-squamous NSCLC patients with impaired renal function.
Source link: https://doi.org/10.1186/s12885-022-10056-x
Background Squamous carcinoma of the anal canal is a human papillomavirus-driven disease with poor prognosis in locally advanced or recurrent settings. Reretifanlimab demonstrated significant clinical growth and an expected safety profile in patients with advanced SCAC who received platinum-based chemotherapy in POD1UM-202. POD1UM-303/InterAct 2, a phase III, double-blind, multiregional study, investigates the addition of retifanlumab to the standard of care carboplatinab in patients with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy, based on these promising findings. Patients are expected to receive and stratified by PD-L1 expression, region, and severity of disease, with inoperable locally recurrent or metastatic SCAC, measurable disease, as per RECIST v1. 1, and no prior systemic chemotherapy or PD-1-directed therapy being administered and stratified by PD-L1 expression, location, and severity of disease. Every 28 days in SOC, patients will be induction cycles of carboplatin and paclitaxel every six cycles.
Source link: https://doi.org/10.3389/fonc.2022.935383
Lessons Learned In this phase II trial in non-small cell lung carcinoma, the lack of effectiveness associated with anti-EGFL7 combined with standard bevacizumab and chemotherapy is consistent with the lack of benefit seen in colorectal carcinoma, highlighting the difficulty of increasing the efficacy of VEGF inhibition in unselected populations. The effectiveness of the anti-EGFL7 antibody, parsatuzumab, in combination with bevacizumab plus platinum-based therapy for acute or recurrent non-small cell lung cancer in this phase II trial was determined. Patients were randomly assigned to either placebo or parsatuzumab in combination with bevacizumab and carboplatin/paclitaxel administered on day 1 of each 21-day cycle. The median PFS was 6. 7 months for the parsatuzumab arm compared to 8. 1 months for the placebo arm. For first-line NS-NCLC, there were no proofs of benefit for parsatuzumab or chemotherapy in the combination of bevacizumab and chemotherapy.
Source link: https://doi.org/10.1634/theoncologist.2017-0690
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions